Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
Abstract Background Major depressive disorder (MDD) is the leading cause of disability worldwide. Response to pharmacologic treatment is generally evaluated by traditional clinician- and patient-reported rating scales. Assessing therapeutic efficacy using the Goal Attainment Scale offers a complementary measure that focuses on recovery-oriented outcomes that patients consider valuable and vital to their well-being. This study aimed to examine outcomes using the Goal Attainment Scale adapted for depression (GAS-D). Methods A phase 4, single-arm, open-label, multicenter study enrolled patients with MDD who were switching antidepressant medication. Patients received vortioxetine 10–20 mg over 12 weeks. Three specific, measurable, attainable, relevant, and time-bound goals were collaboratively set by patients with their clinicians. One goal was determined by the patient’s self-defined objectives; 2 were related to predefined domain categories. Prespecified domains included psychological, motivational, emotional, physical/functional, and cognitive categories. The primary endpoint was the proportion of patients who achieved a GAS-D score ≥ 50 at week 12. Secondary and exploratory endpoints included changes from baseline in several clinical and patient-reported measures of depression and cognitive function. Safety and tolerability were also assessed. Results At week 12, of the 122 adults participating in the study, 57.8% achieved a GAS-D score ≥ 50. Depression severity, cognitive function, cognitive performance, well-being, employment, and quality of life also significantly improved. Treatment response and remission rates were 65 and 40%, respectively. Vortioxetine was well tolerated, with adverse events consistent with product labeling. Conclusions A majority of patients with MDD switching to vortioxetine achieved their treatment goals, including improvement in specific functional outcomes relating to physical and emotional goals, as assessed by the GAS-D and standard patient- and clinician-reported measures. When assayed for convergent validity in a separate analysis, changes in goal scores on the GAS-D were statistically significantly correlated with multiple commonly used clinical measures of depression assessed in this study. The GAS-D approach provides a new patient-centric paradigm for the collaborative development and assessment of progress toward meaningful treatment goals, contributing to a comprehensive evaluation of treatment outcomes in patients with MDD. Longer studies against a control intervention are justified. Trial registration ClinicalTrials.gov identifier: NCT02972632 . Registered 21 November 2016..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
BMC Psychiatry - 21(2021), 1, Seite 10 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Maggie McCue [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
Goal achievement |
---|
doi: |
10.1186/s12888-021-03608-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ015841340 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ015841340 | ||
003 | DE-627 | ||
005 | 20230310075520.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230226s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12888-021-03608-1 |2 doi | |
035 | |a (DE-627)DOAJ015841340 | ||
035 | |a (DE-599)DOAJ9d99f5a39bd94a74abe97c12e4e058b2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC435-571 | |
100 | 0 | |a Maggie McCue |e verfasserin |4 aut | |
245 | 1 | 0 | |a Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Background Major depressive disorder (MDD) is the leading cause of disability worldwide. Response to pharmacologic treatment is generally evaluated by traditional clinician- and patient-reported rating scales. Assessing therapeutic efficacy using the Goal Attainment Scale offers a complementary measure that focuses on recovery-oriented outcomes that patients consider valuable and vital to their well-being. This study aimed to examine outcomes using the Goal Attainment Scale adapted for depression (GAS-D). Methods A phase 4, single-arm, open-label, multicenter study enrolled patients with MDD who were switching antidepressant medication. Patients received vortioxetine 10–20 mg over 12 weeks. Three specific, measurable, attainable, relevant, and time-bound goals were collaboratively set by patients with their clinicians. One goal was determined by the patient’s self-defined objectives; 2 were related to predefined domain categories. Prespecified domains included psychological, motivational, emotional, physical/functional, and cognitive categories. The primary endpoint was the proportion of patients who achieved a GAS-D score ≥ 50 at week 12. Secondary and exploratory endpoints included changes from baseline in several clinical and patient-reported measures of depression and cognitive function. Safety and tolerability were also assessed. Results At week 12, of the 122 adults participating in the study, 57.8% achieved a GAS-D score ≥ 50. Depression severity, cognitive function, cognitive performance, well-being, employment, and quality of life also significantly improved. Treatment response and remission rates were 65 and 40%, respectively. Vortioxetine was well tolerated, with adverse events consistent with product labeling. Conclusions A majority of patients with MDD switching to vortioxetine achieved their treatment goals, including improvement in specific functional outcomes relating to physical and emotional goals, as assessed by the GAS-D and standard patient- and clinician-reported measures. When assayed for convergent validity in a separate analysis, changes in goal scores on the GAS-D were statistically significantly correlated with multiple commonly used clinical measures of depression assessed in this study. The GAS-D approach provides a new patient-centric paradigm for the collaborative development and assessment of progress toward meaningful treatment goals, contributing to a comprehensive evaluation of treatment outcomes in patients with MDD. Longer studies against a control intervention are justified. Trial registration ClinicalTrials.gov identifier: NCT02972632 . Registered 21 November 2016. | ||
650 | 4 | |a Major depressive disorder | |
650 | 4 | |a Vortioxetine | |
650 | 4 | |a Goal attainment | |
650 | 4 | |a Goal achievement | |
653 | 0 | |a Psychiatry | |
700 | 0 | |a Sara Sarkey |e verfasserin |4 aut | |
700 | 0 | |a Anna Eramo |e verfasserin |4 aut | |
700 | 0 | |a Clement François |e verfasserin |4 aut | |
700 | 0 | |a Sagar V. Parikh |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t BMC Psychiatry |d BMC, 2003 |g 21(2021), 1, Seite 10 |w (DE-627)DOAJ000049468 |x 1471244X |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g pages:10 |
856 | 4 | 0 | |u https://doi.org/10.1186/s12888-021-03608-1 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/9d99f5a39bd94a74abe97c12e4e058b2 |z kostenfrei |
856 | 4 | 0 | |u https://doi.org/10.1186/s12888-021-03608-1 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1471-244X |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 21 |j 2021 |e 1 |h 10 |